Related Experiment Videos
[Application of immunotoxin in cancer therapy; its usefulness and problems in the future]
T Yamaguchi1, T Takahashi, K Kitamura
1Dept. of Surgery, Kyoto Prefectural University of Medicine.
Abstract:
Highly specific anti-human colorectal carcinoma monoclonal antibody(A7) was developed by fusion of mouse myeloma cells with mouse spleen cells immunized by colon cancer cells. Neocarzinostatin (NCS) was bound to A7 preserving both antibody and drug activities. This conjugate (A7-NCS) was applied for clinical trial. No serious side effects were reported, and half of the eight patients with metastatic liver tumor responded to A7-NCS well. To overcome the variety in the expression of tumor-specific antigen on tumor cells, new types of conjugates were developed. Mitomycin C(MMC) was bound to Dextran sulphate. And this conjugate (M MC-Dex) was bound to A7 with the expectation that MMC would release from Dextran that was delivered to the surface of the cancer cells. This type of conjugate would be effective not only against cancer cells that express antigens detected by A7 but also against any cells around cancer cells detected by A7. The possibility and problems in cancer therapy using immunotoxin are discussed.
Insights
A novel immunotoxin conjugate (A7-NCS) showed promising results in treating metastatic liver tumors, with half of patients responding well. Further development aims to broaden efficacy against diverse colorectal cancer cells.
Area of Science:
- Oncology
- Immunology
- Bioconjugation
Background:
- Colorectal carcinoma exhibits variable tumor-specific antigen expression, complicating targeted therapy.
- Monoclonal antibodies offer specificity but require strategies to enhance cytotoxic payload delivery.
- Immunotoxins combine antibody targeting with potent drug activity for cancer treatment.
Purpose of the Study:
- To develop and evaluate an anti-human colorectal carcinoma immunotoxin conjugate (A7-NCS).
- To explore novel conjugate designs (A7-MMC-Dex) to overcome antigen heterogeneity in colorectal cancer.
- To assess the therapeutic potential and challenges of immunotoxin-based cancer therapy.
Main Methods:
- Development of a highly specific anti-colorectal carcinoma monoclonal antibody (A7).
- Conjugation of Neocarzinostatin (NCS) to the A7 antibody (A7-NCS).
- Creation of a novel conjugate (A7-MMC-Dex) linking Mitomycin C (MMC) via Dextran sulfate to the A7 antibody.
Main Results:
- The A7-NCS conjugate demonstrated preservation of both antibody and drug activities.
- Clinical trials of A7-NCS in metastatic liver tumor patients showed good response in 50% of cases with no serious side effects.
- The A7-MMC-Dex conjugate design aims for broader efficacy against antigen-variable cancer cells and surrounding tumor microenvironment.
Conclusions:
- A7-NCS represents a promising immunotoxin for metastatic colorectal cancer treatment.
- Novel conjugate strategies are crucial for addressing tumor antigen heterogeneity.
- Immunotoxin therapy holds potential but requires careful consideration of design and delivery mechanisms.